A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...

Once-weekly semaglutide 2.4 mg significantly reduced steatohepatitis and liver fibrosis symptoms among adults with metabolic ...

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.

A global trial finds Wegovy and Ozempic significantly improve liver health in patients and treats those with advanced fatty ...

So, there's this scientist, Arun Sanyal, M.D., who's the director of the VCU Stravitz-Sanyal Institute for Liver Disease and ...

Semaglutide, a drug commonly taken for weight loss, showed marked benefits for most patients in a trial for metabolic ...

Semaglutide, a GLP-1 receptor agonist sold under brand names Wegovy and Ozempic, is approved for weight loss and blood sugar ...

In a significant medical breakthrough, researchers from King’s College London have found that semaglutide, a drug commonly ...

Novo Nordisk Canada announced that Health Canada has accepted for review, under the Priority Review policy, its supplemental ...

Health Canada begins a priority review of semaglutide 2.4 mg, a weekly treatment by Novo Nordisk for MASH, a liver disease ...